pdf

Law360: Fresenius Loses ‘Unduly Speculative’ Generic Drug Row

February 25, 2020

O’Melveny represented Par Pharmaceuticals in its win over Fresenius Kabi, which accused Par of violating antitrust laws, this article reported. Law360 noted that Judge Wigenton called Fresenius Kabi’s suit “unduly speculative and procedurally burdensome.”

The O’Melveny team that represented Par Pharmaceuticals included partners Benjamin Bradshaw and Brett Williamson, and counsel Stephen McIntyre.